Tuesday Dec 10, 2024

Blarcamesine Demonstrates Promising Outcomes in Alzheimer’s Treatment Trial

Anavex Life Sciences has announced promising findings from their Phase 2b/3 trial of blarcamesine, a novel therapeutic candidate for early Alzheimer’s disease (AD). The investigational drug, also known as ANAVEX2-73, by Anavex, showed significant efficacy in reducing amyloid-ß biomarkers and slowing cognitive decline in patients.  The multicenter, randomized, double-blind, placebo-controlled study involved 508 participants from […]

Back to Top